The Traderszone Network

Published in TZ Latest News 20 September, 2016 by The TZ Newswire Staff

Allergan is paying a stunning 500% premium to buy a clinical-stage biotech

The usual premium on a company with no approved drugs is closer to 50% to 100%, says RBC.
read more